Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed non-small cell lung cancer~  * No squamous cell carcinoma~ * No histology in close proximity to a major vessel~* Resectable stage IB-IIIA disease~* No CNS or brain metastases~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 8.0 g/dL~* Bilirubin normal~* Creatinine ≤ 1.5 mg/dL~* Urine protein:creatinine \< 1.0~* Alkaline phosphatase (AP), AST, and ALT must meet 1 of the following criteria:~  * AP normal AND AST and ALT ≤ 5 times upper limit of normal (ULN)~ * AP ≤ 2.5 times ULN AND AST and ALT ≤ 1.5 times ULN~ * AP ≤ 5 times ULN AND AST and ALT normal~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for at least 3 months after completion of study treatment~* Adequate pulmonary and cardiovascular function to tolerate surgical resection~* No cavitation or history of hemoptysis (i.e., bright red blood ≥ ½ teaspoon)~* No existing peripheral neuropathy ≥ grade 1~* No known history of severe hypersensitivity reaction to drugs formulated with polysorbate 80~* No history of serious systemic disease, including any of the following:~  * Myocardial infarction within the past 6 months~ * Uncontrolled hypertension (i.e., blood pressure \> 150/110 mm Hg on medication)~ * Unstable angina~ * New York Heart Association class II-IV congestive heart failure~ * Unstable symptomatic arrhythmia requiring medication~    * Patients with chronic atrial arrhythmia (i.e., atrial fibrillation or paroxysmal supraventricular tachycardia) are eligible~ * Clinically significant peripheral vascular disease (i.e., grade II or higher)~* No history of significant neurological or psychiatric condition~* No known active infection within the past 14 days~* No serious, nonhealing wound, ulcer, or bone fracture~* No evidence of bleeding diathesis or coagulopathy~* No stroke within the past 6 months~* No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days~* No other serious illness or medical condition~* No active infection~* No other currently active malignancy except nonmelanoma skin cancer~  * Malignancies for which therapy has been completed and are considered to have ≤ 30% chance of risk of relapse are not considered active~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy or VEGF inhibitor~* No prior (i.e., within the past 4 weeks), concurrent, or anticipated participation in another experimental drug study except a Genentech-sponsored bevacizumab cancer study~* No major surgical procedure, open biopsy, or significant traumatic injury within the past 28 days~* No anticipation for major surgical procedure during study treatment~* No fine-needle aspiration or core biopsy within 7 days prior to study entry~* No concurrent full-dose anticoagulation~* No other concurrent chemotherapy, immunotherapy, radiotherapy, or investigational therapy for this cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues